Boston Scientific(BSX.US) 首季业绩胜华尔街预期,惟该医疗器材供应商于周三下调全年指引。截至3月季度,经调整盈利由去年同期的$0.75升至$0.80,纯销售额按年升近12%至$5.20 billion。FactSet调查的市场预期分别为$0.79及$5.17 billion。期内心血管业务销售额按年升13.5%至$3.50 billion。MedSurg部门升7.8%至$...
Source LinkBoston Scientific(BSX.US) 首季业绩胜华尔街预期,惟该医疗器材供应商于周三下调全年指引。截至3月季度,经调整盈利由去年同期的$0.75升至$0.80,纯销售额按年升近12%至$5.20 billion。FactSet调查的市场预期分别为$0.79及$5.17 billion。期内心血管业务销售额按年升13.5%至$3.50 billion。MedSurg部门升7.8%至$...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.